P1‐058: Nilvad: An Investigator Driven Phase III Multi Centre European Clinical Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease

trations of lithium were maintained at a range of 0.4-0.8mmol/L. We assessed verbal memory using delayed recall in Hopkins Verbal Learning Test-Revised (HVLT-R) at the start and end of treatment. Repeated-measures ANOVAwas used to compare delayed recall zscores over time, with cumulative lithium dose as a covariate. We also assessed stroke severity (National Institutes of Health Stroke Scale (NIHSS)) and cognition (Montreal Cognitive Assessment (MoCA), Standardized Mini-Mental State Evaluation (sMMSE)) at baseline and termination. Results: To date, 11 patients (45% male, mean (SD) age 1⁄4 70.3 (12.1), sMMSE 1⁄4 26.8 (3.4), MoCA 1⁄4 20.9 (5.0), HVLT-R delayed recall z-score 1⁄4 -1.3 (1.0)) have been recruited, on average, 87 (668) days after mild stroke (NIHSS score 2). Cumulative lithium dose received ranged from 0 (screen drop) to 26850 mg. Lithium was discontinued in 3 patients due to tolerability issues but there were no serious adverse events. Cumulative lithium dose was significantly associated with improvement in delayed recall over time (F1⁄45.41, p1⁄40.045). There was no change in the other measures. Conclusions:These initial results suggest that lithium treatment is tolerated by many post-stroke patients, and may be associated with improved verbal memory after stroke, with a preliminary signal suggesting a dose response relationship. These findings are consistent with lithium’s suggested neuroprotective and neurotrophic effects.